A detailed history of Walleye Capital LLC transactions in Uni Qure N.V. stock. As of the latest transaction made, Walleye Capital LLC holds 90,142 shares of QURE stock, worth $1.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
90,142
Holding current value
$1.57 Million
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.78 - $10.12 $340,736 - $912,237
90,142 New
90,142 $444,000
Q1 2024

May 15, 2024

SELL
$4.82 - $6.93 $287,214 - $412,944
-59,588 Reduced 42.33%
81,167 $422,000
Q4 2023

Feb 14, 2024

BUY
$5.63 - $8.27 $83,194 - $122,205
14,777 Added 11.73%
140,755 $952,000
Q3 2023

Nov 14, 2023

BUY
$6.71 - $11.83 $845,312 - $1.49 Million
125,978 New
125,978 $845,000
Q1 2023

May 15, 2023

BUY
$18.7 - $23.07 $1.96 Million - $2.41 Million
104,642 New
104,642 $2.11 Million
Q3 2022

Nov 14, 2022

BUY
$16.98 - $25.54 $170,920 - $257,085
10,066 Added 45.49%
32,196 $604,000
Q2 2022

Aug 08, 2022

BUY
$13.15 - $20.45 $33,282 - $51,758
2,531 Added 12.91%
22,130 $413,000
Q1 2022

May 16, 2022

BUY
$14.54 - $21.5 $284,969 - $421,378
19,599 New
19,599 $354,000
Q2 2020

Aug 14, 2020

SELL
$45.06 - $67.74 $37,895 - $56,969
-841 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$40.01 - $73.97 $206,411 - $381,611
-5,159 Reduced 85.98%
841 $40,000
Q3 2019

Nov 14, 2019

SELL
$39.36 - $76.8 $255,879 - $499,276
-6,501 Reduced 52.0%
6,000 $236,000
Q2 2019

Aug 14, 2019

BUY
$52.76 - $82.19 $595,976 - $928,418
11,296 Added 937.43%
12,501 $976,000
Q1 2019

May 15, 2019

BUY
$27.39 - $68.41 $33,004 - $82,434
1,205 New
1,205 $72,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $813M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.